Lap gastric sleeve CPT coding is a key reference point for clinicians, coders, and patients navigating bariatric surgery documentation across international healthcare systems. Laparoscopic sleeve gastrectomy — one of the most commonly performed weight-loss procedures in the UK — involves removing approximately 75–80% of the stomach to restrict intake and reduce hunger hormones. Whether you are seeking to understand CPT code 43775, NHS referral pathways, NICE eligibility criteria, or what to expect from recovery and long-term follow-up, this guide provides clear, clinically accurate information aligned with UK guidance from NICE, BOMSS, and the NHS.

What Is Laparoscopic Gastric Sleeve Surgery?

Laparoscopic sleeve gastrectomy removes approximately 75–80% of the stomach via keyhole surgery, reducing food intake and lowering ghrelin levels to suppress appetite and support sustained weight loss.

Have any more questions about this? Message our pharmaceutical team to get more info →

Laparoscopic sleeve gastrectomy, commonly referred to as a gastric sleeve, is a form of bariatric (weight-loss) surgery in which approximately 75–80% of the stomach is surgically removed, leaving a narrow, sleeve-shaped tube. The procedure is performed laparoscopically — through small keyhole incisions in the abdomen — using a camera and specialised surgical instruments, which significantly reduces recovery time compared with open surgery.

The mechanism by which sleeve gastrectomy promotes weight loss is twofold. First, the dramatically reduced stomach volume restricts the amount of food a patient can consume at any one time. Second, the removal of the fundus — the upper portion of the stomach — substantially reduces the production of ghrelin, a hormone that stimulates hunger. Changes in other gut hormones, including GLP-1 and PYY, also contribute to appetite regulation and metabolic improvement following the procedure. These hormonal effects are a key differentiator from purely restrictive procedures and contribute to sustained appetite suppression beyond the immediate post-operative period.

Sleeve gastrectomy is one of the most commonly performed bariatric procedures in the United Kingdom, with outcomes documented through the National Bariatric Surgery Registry (NBSR) and supported by guidance from the British Obesity and Metabolic Surgery Society (BOMSS). It is considered a definitive standalone procedure, though in some cases it may serve as a first-stage operation for patients with very high BMI, prior to a more complex procedure such as a Roux-en-Y gastric bypass. Unlike gastric banding, it does not involve the implantation of a foreign device, and unlike bypass surgery, it does not reroute the intestines, making it a comparatively straightforward bariatric option with a well-documented safety profile in appropriately selected patients.

CPT Coding for Laparoscopic Sleeve Gastrectomy Explained

CPT code 43775 is the designated US billing code for laparoscopic sleeve gastrectomy; the UK equivalent is OPCS-4 code G27.8 with laparoscopic modifier Y75.2, used alongside ICD-10 obesity diagnosis code E66.

CPT (Current Procedural Terminology) codes are a standardised set of medical codes developed and maintained by the American Medical Association (AMA). They are used primarily within the United States healthcare system to document and bill for medical, surgical, and diagnostic procedures. Although CPT codes are not used within the NHS or standard UK private healthcare billing systems — which instead rely on OPCS-4 procedure codes and ICD-10 diagnostic codes — they are frequently referenced in international medical literature, research, and by UK-based professionals working across borders or within internationally affiliated private institutions.

For laparoscopic sleeve gastrectomy, the relevant CPT code is 43775, defined in the AMA CPT codebook as: Laparoscopy, surgical, gastric restrictive procedure; longitudinal gastrectomy (i.e., sleeve gastrectomy). This code was introduced to reflect the standalone nature of the procedure and to distinguish it from other bariatric interventions. Related codes that may appear in documentation include:

• 43770 – Laparoscopic adjustable gastric band placement

• 43644 – Laparoscopic Roux-en-Y gastric bypass

Note: there is no single current CPT code specifically designated for open sleeve gastrectomy; clinicians and coders should refer to the current AMA CPT codebook or CPT Assistant for guidance on any such cases.

In the UK, sleeve gastrectomy is typically coded using OPCS-4 code G27.8 (Other specified partial excision of stomach) combined with Y75.2 (Laparoscopic approach to abdominal cavity). Local coding departments should validate this mapping against the current NHS Digital OPCS-4 release and any relevant NHS Coding Clinic advice, as coding practice may vary. The accompanying ICD-10 diagnosis code for obesity (E66.–) should be recorded alongside the OPCS-4 procedural code in UK clinical records, in line with standard NHS coding practice.

UK clinicians and coders should be aware that CPT code 43775 may appear in imported clinical documentation, insurance pre-authorisation forms from international insurers, or academic publications, and should map these appropriately to the correct OPCS-4 equivalent when processing UK records. Accurate procedural coding is essential for clinical audit, commissioning data, and reimbursement purposes.

NHS and Private Referral Pathways for Bariatric Surgery

NHS patients in England must complete a tier 3 weight management programme before referral to a tier 4 surgical centre; private patients follow a more streamlined pathway but should still use CQC-registered, BOMSS-credentialled providers.

In England, access to bariatric surgery through the NHS is governed by NHS England commissioning policies and aligned with NICE guidance (CG189). Patients are typically referred by their GP to a specialist tier 3 weight management service — a community-based, multidisciplinary programme that includes dietary, psychological, and physical activity support. Engagement with this tier 3 service is generally required before a referral to a tier 4 surgical service is considered; however, the minimum duration of tier 3 engagement is locally determined by individual Integrated Care Boards (ICBs) and may differ across England and the devolved nations. This staged approach ensures that surgery is offered only when non-surgical interventions have been appropriately explored.

Once referred to a tier 4 bariatric surgical centre, patients undergo a comprehensive pre-operative assessment involving a multidisciplinary team (MDT) that typically includes a bariatric surgeon, specialist dietitian, clinical psychologist or psychiatrist, and specialist nurse. This assessment evaluates medical suitability, psychological readiness, and the patient's understanding of the lifelong dietary and lifestyle changes required post-surgery.

For patients pursuing surgery through the private sector, the pathway is generally more streamlined, though reputable private providers will still conduct thorough pre-operative assessments and adhere to the same clinical standards. Patients should ensure their chosen provider is registered with the Care Quality Commission (CQC) and that the operating surgeon holds appropriate credentials with BOMSS. Participation by the provider in the NBSR is a further indicator of commitment to quality and outcomes monitoring. It is advisable for patients to inform their NHS GP of any planned private bariatric procedure, as post-operative care — including nutritional monitoring and management of complications — may involve NHS services. Continuity of care between private and NHS providers is an important patient safety consideration.

Eligibility Criteria and NICE Guidelines for Sleeve Gastrectomy

NICE CG189 recommends bariatric surgery for adults with a BMI ≥40 kg/m², or ≥35 kg/m² with a significant comorbidity, after non-surgical options have failed; reduced BMI thresholds apply to certain minority ethnic groups.

NICE guidance (CG189) sets out clear eligibility criteria for bariatric surgery in adults. Patients are generally considered eligible if they meet the following criteria:

• BMI of 40 kg/m² or above, or

• BMI of 35–39.9 kg/m² with a significant obesity-related comorbidity such as type 2 diabetes, hypertension, obstructive sleep apnoea, or non-alcoholic fatty liver disease

• All appropriate non-surgical measures have been tried but have failed to achieve or maintain adequate clinically beneficial weight loss

• The patient is fit for anaesthesia and surgery

• The patient commits to long-term follow-up

NICE CG189 also recommends that bariatric surgery should be considered as a first-line option for adults with a BMI over 50 kg/m², where surgical intervention may be more clinically appropriate than prolonged conservative management.

Importantly, NICE guidance supports expedited assessment for bariatric surgery in adults with a BMI of 35 kg/m² or above and recent-onset type 2 diabetes, and recommends that surgery be considered for adults with a BMI of 30–34.9 kg/m² who also have recent-onset type 2 diabetes. For people from some minority ethnic groups (including South Asian, Chinese, other Asian, Middle Eastern, Black African, and African-Caribbean backgrounds), NICE and public health guidance recommend applying reduced BMI thresholds of approximately 2.5 kg/m² when assessing metabolic risk and surgical eligibility, reflecting the higher cardiometabolic risk at lower body weights in these populations.

Sleeve gastrectomy is one of the approved procedures under these guidelines, alongside gastric bypass and adjustable gastric banding. The choice of procedure is made collaboratively between the patient and the MDT, taking into account individual clinical factors, patient preference, and the presence of conditions such as gastro-oesophageal reflux disease (GORD) — which may favour bypass over sleeve in some cases. Patients should be made aware that NICE guidance represents a minimum standard, and individual NHS trusts or commissioners may apply additional local criteria.

Risks, Benefits, and Expected Outcomes of the Procedure

Laparoscopic sleeve gastrectomy offers significant comorbidity improvement and excess weight loss, but carries risks including staple line leak, GORD, nutritional deficiencies, and potential weight regain if lifestyle changes are not maintained.

Laparoscopic sleeve gastrectomy carries a well-documented and generally favourable benefit-to-risk profile when performed in appropriately selected patients at accredited centres. Based on UK data from the NBSR and BOMSS, patients can anticipate the following expected outcomes:

• Excess weight loss of approximately 50–70% within the first 12–18 months post-operatively, though results vary by centre and individual factors

• Significant improvement or remission of obesity-related comorbidities, including type 2 diabetes (remission rates broadly in the range of 50–60% at one to two years), hypertension, dyslipidaemia, and obstructive sleep apnoea

• Improved quality of life, mobility, and psychological wellbeing

• Reduced long-term cardiovascular risk

However, as with any surgical procedure, sleeve gastrectomy carries risks that must be clearly communicated during the consent process. Short-term risks include bleeding, staple line leak (UK registry data suggest rates of approximately 1–2%, representing the most serious early complication), infection, venous thromboembolism, and anaesthetic complications. Longer-term risks include:

• Gastro-oesophageal reflux disease (GORD) — sleeve gastrectomy can worsen or precipitate GORD in some patients, which may require medical management or, in refractory cases, conversion to gastric bypass

• Nutritional deficiencies — particularly of vitamin B12, iron, vitamin D, folate, and thiamine, necessitating lifelong supplementation and monitoring

• Gallstone formation — rapid weight loss increases the risk of gallstones in the post-operative period

• Weight regain — possible if dietary and lifestyle changes are not maintained

• Stricture or stenosis of the gastric sleeve

• Psychological changes — including altered body image, relationship changes, and shifts in emotional eating patterns

Patients should be advised to seek urgent medical attention if they experience persistent vomiting, severe abdominal pain, fever, rapid heart rate, chest pain, or breathlessness in the post-operative period, as these may indicate a staple line leak, pulmonary embolism, or other serious complication. In the event of chest pain, breathlessness, or collapse, patients should call 999 immediately. If prolonged vomiting occurs, prompt assessment for thiamine deficiency is important, as this can cause serious neurological complications if untreated.

Recovery, Follow-Up Care, and Long-Term Support

Most patients are discharged within one to two nights and return to full activity within four to six weeks; lifelong nutritional supplementation and annual blood monitoring are mandatory, with ongoing bariatric MDT follow-up strongly recommended.

The immediate post-operative recovery period for laparoscopic sleeve gastrectomy typically involves a hospital stay of one to two nights, with most patients returning to light activities within two to four weeks and to full activity within four to six weeks. Prior to surgery, patients are usually advised to follow a liver-reduction (low-calorie) diet for two to four weeks to reduce liver size and facilitate safe laparoscopic access; smoking cessation and reduction of alcohol intake are also strongly recommended before and after surgery.

A structured dietary progression is essential in the weeks following surgery, moving through stages from clear fluids to puréed foods, soft foods, and eventually a modified solid diet. This progression is guided by the bariatric dietitian and must be followed carefully to protect the integrity of the staple line and allow the stomach to heal.

Nutritional supplementation is a lifelong requirement following sleeve gastrectomy. In line with BOMSS guidance, patients are typically advised to take:

• A complete bariatric multivitamin daily

• Vitamin D and calcium supplements

• Vitamin B12 — intramuscular (IM) injection every three months is the recommended route after sleeve gastrectomy; oral or sublingual preparations may be used in some circumstances but should be guided by individual blood results and clinical assessment

• Iron supplementation, particularly in pre-menopausal women

• Additional supplementation as directed by individual blood results

Regular blood tests to monitor nutritional status are recommended at three months, six months, and twelve months post-operatively, and annually thereafter, in line with BOMSS and NICE CG189 guidance. The standard panel includes: full blood count (FBC), ferritin, vitamin B12, folate, urea and electrolytes (U&E), liver function tests (LFTs), calcium, vitamin D, and parathyroid hormone (PTH). Thiamine levels should be checked if there are concerns about prolonged vomiting or inadequate intake. These tests should be arranged through the patient's GP or bariatric follow-up clinic.

Patients planning a pregnancy should be advised to avoid conception for at least 12–18 months after surgery, when weight is more stable. Those planning pregnancy should seek advice from their bariatric team and GP regarding higher-dose folic acid supplementation and optimisation of nutritional status prior to conception.

Long-term success following sleeve gastrectomy is strongly associated with engagement in ongoing support. This includes regular follow-up with the bariatric MDT, participation in support groups, and sustained commitment to dietary and lifestyle changes. Psychological support should remain accessible, as body image concerns, relationship changes, and emotional eating patterns may emerge or persist after surgery.

Patients experiencing significant weight regain, worsening reflux, or new symptoms should be referred back to their bariatric team for reassessment. In some cases, revision surgery may be considered. The long-term relationship between the patient and their bariatric care team is a cornerstone of sustained outcomes and overall wellbeing.

Any suspected adverse reactions to medicines or medical devices used in connection with bariatric surgery should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions